Calamos Advisors LLC Invests $1.05 Million in Adaptive Biotechnologies Corporation (NASDAQ:ADPT)

Calamos Advisors LLC acquired a new stake in shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Free Report) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 140,889 shares of the company's stock, valued at approximately $1,047,000. Calamos Advisors LLC owned 0.09% of Adaptive Biotechnologies at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Cibc World Markets Corp purchased a new position in Adaptive Biotechnologies in the 4th quarter worth about $65,000. Bridgefront Capital LLC bought a new position in shares of Adaptive Biotechnologies in the 4th quarter worth approximately $80,000. Wealth Enhancement Advisory Services LLC bought a new position in shares of Adaptive Biotechnologies in the 1st quarter worth approximately $87,000. Amundi lifted its stake in shares of Adaptive Biotechnologies by 41.2% in the 4th quarter. Amundi now owns 15,532 shares of the company's stock worth $93,000 after purchasing an additional 4,531 shares during the period. Finally, Proficio Capital Partners LLC bought a new position in shares of Adaptive Biotechnologies in the 4th quarter worth approximately $93,000. 99.17% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. Craig Hallum started coverage on shares of Adaptive Biotechnologies in a research note on Wednesday, June 18th. They issued a "buy" rating and a $15.00 price objective on the stock. Morgan Stanley raised their price objective on shares of Adaptive Biotechnologies from $7.00 to $9.00 and gave the company an "equal weight" rating in a research report on Monday, May 5th. The Goldman Sachs Group raised their price objective on shares of Adaptive Biotechnologies from $9.00 to $10.00 and gave the company a "buy" rating in a research report on Friday, May 2nd. Finally, Piper Sandler restated an "overweight" rating and set a $13.00 price objective (up from $11.00) on shares of Adaptive Biotechnologies in a research report on Tuesday, May 6th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $10.57.

Adaptive Biotechnologies Trading Up 1.3%

ADPT traded up $0.15 during trading on Thursday, hitting $12.08. 2,653,322 shares of the company traded hands, compared to its average volume of 2,054,060. Adaptive Biotechnologies Corporation has a 1 year low of $3.51 and a 1 year high of $12.43. The company has a market cap of $1.84 billion, a PE ratio of -12.58 and a beta of 1.83. The stock's 50-day simple moving average is $10.09 and its two-hundred day simple moving average is $8.42.

Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The company reported ($0.20) EPS for the quarter, topping analysts' consensus estimates of ($0.28) by $0.08. Adaptive Biotechnologies had a negative net margin of 74.84% and a negative return on equity of 62.79%. The business had revenue of $52.44 million during the quarter, compared to analysts' expectations of $42.13 million. During the same period last year, the company posted ($0.33) EPS. The business's revenue was up 25.2% on a year-over-year basis. Equities analysts expect that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current year.

Insider Activity at Adaptive Biotechnologies

In other Adaptive Biotechnologies news, insider Harlan S. Robins sold 68,412 shares of Adaptive Biotechnologies stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $7.35, for a total value of $502,828.20. Following the completion of the transaction, the insider directly owned 1,279,524 shares of the company's stock, valued at $9,404,501.40. This trade represents a 5.08% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 6.40% of the stock is owned by insiders.

About Adaptive Biotechnologies

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.